Source comparison
PT-141 Appetite Control Research Mechanism: Comparison
Mechanism MC3R/MC4R agonist. Hypothalamic satiety pathway GLP-1 receptor agonist. Incretin mimetic MC4R agonist. Genetic obesity indication PT-141 acts centrally without gut involvement; semaglutide modulates digestive physiology; setmelanotide is FDA-approved
This comparison does not assign a generated winner or score.
- Mechanism
- MC3R/MC4R agonist. Hypothalamic satiety pathway
- GLP-1 receptor agonist. Incretin mimetic
- MC4R agonist. Genetic obesity indication
- PT-141 acts centrally without gut involvement; semaglutide modulates digestive physiology; setmelanotide is FDA-approved for rare genetic obesity
- FDA Approval
- Sexual dysfunction only
- Obesity, Type 2 diabetes
- Genetic obesity (POMC, LEPR deficiency)
- Only setmelanotide has metabolic approval; PT-141's appetite effect is incidental
- Half-Life
- ~2.7 hours
- ~7 days (weekly dosing)
- ~1.5 hours (daily dosing)
- PT-141 and setmelanotide require frequent administration; semaglutide offers convenience
- GI Side Effects
- Minimal. No gastric slowing
- Nausea, vomiting common (30–45%)
- Hyperpigmentation, injection-site reactions
- PT-141 avoids GI distress but lacks long-term safety data for metabolic use
- Weight Loss Data (Human Trials)
- None. Sexual dysfunction trials only
- 14.9% mean reduction at 68 weeks (STEP-1)
- 10.3% mean reduction in POMC deficiency (52 weeks)
- Semaglutide has robust metabolic evidence; PT-141 has none